Navigation Links
Boston Scientific Announces Three FDA Product Approvals for Its Cardiac Rhythm Management Business

Approvals include CONFIENT(TM) ICD, LIVIAN(TM) CRT-D and upgraded

LATITUDE(R) Patient Management System

NATICK, Mass., Feb. 25 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) approval for three products in its Cardiac Rhythm Management business. They are:

-- The CONFIENT(TM) implantable cardioverter defibrillator (ICD), which

helps protect patients at risk of sudden cardiac death

-- The LIVIAN(TM) cardiac resynchronization therapy defibrillator

(CRT-D), which provides cardiac resynchronization and defibrillation

therapies in one device

-- An upgraded LATITUDE(R) Patient Management System, with enhanced

remote monitoring capabilities

"Our Cardiac Rhythm Management (CRM) team is refocused on delivering therapy systems that meet physicians' needs for safety, reliability and better patient outcomes," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "These and other recent approvals are tangible examples of the team's revitalized commitment to quality and innovation."


The CONFIENT ICD features an enhanced AV (atrial ventricular) Search Hysteresis feature designed to reduce unnecessary right ventricular pacing. The device is equipped with wireless capability designed to save physicians time during implant by allowing device programming during wound closure and eliminating the need for the programming wand in the sterile field. Wireless capability also saves time at follow-up visits by offering device interrogations that can be three times faster than the Company's wanded telemetry.


The LIVIAN CRT-D enables physicians to provide patients with individualized therapy using the following features:

-- SmartDelay(TM): quickly proposes programmable device settings, which

enables physicians to tailor individualized pacing therapies for their


-- Bi-V Trigger with ventricular rate regulation: helps physicians manage

heart failure patients with frequent atrial arrhythmias

Upgraded LATITUDE Patient Management System The upgraded LATITUDE Patient Management system has enhanced remote monitoring capabilities that include:

-- A new alert in the CONFIENT ICD that notifies physicians if a

patient's percentage of right ventricular pacing increases above a

programmable threshold

-- A new alert in the LIVIAN CRT-D that notifies physicians if a

patient's percentage of biventricular pacing falls below a

programmable threshold

-- A programmable atrial arrhythmia burden alert in the CONFIENT ICD and

the LIVIAN CRT-D that enables physicians to detect and manage

arrhythmias. Patients with atrial fibrillation, particularly those

with heart failure, are at risk of stroke. By identifying arrhythmias

earlier, physicians can intervene with treatments to decrease this


Both the CONFIENT ICD and LIVIAN CRT-D enable physicians to manage their patients wirelessly on the LATITUDE Patient Management System. The LATITUDE system helps physicians impact patient outcomes by notifying them of changes in a patient's clinical status between normally scheduled follow-ups, enabling them to intervene earlier in a patient's care.

"These technologies are welcome improvements that are designed to provide earlier insight into changing patient conditions and enable me to devote time to patients who need me the most," said Brian Olshansky, M.D., Professor of Medicine, University of Iowa Hospitals.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit:

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward- looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our product performance, regulatory approval of our products, competitive offerings, our growth strategy, and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A -- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A -- Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward- looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT: Paul Donovan

508-650-8541 (office)

508-667-5165 (mobile)

Media Relations

Boston Scientific Corporation

Larry Neumann

508-650-8696 (office)

Investor Relations

Boston Scientific Corporation

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents
2. Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007
3. Boston Scientific to Participate in Merrill Lynch Conference
4. CryoCor to Highlight Products at 13th Annual International Boston Atrial Fibrillation Symposium
5. Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses
6. Boston Scientific Completes Sale of Auditory Business and Drug Pump Development Program
7. Boston Scientific Announces Results for Third Quarter Ended September 30, 2007
8. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
9. The 58th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, Nov. 2-6
10. Boston Scientific Announces European Approval of Next-Generation Implantable Defibrillator
11. Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetixs Medical Advisory Board
Post Your Comments:
(Date:11/25/2015)... --> ... 2020 report analyzes that automating biobanking workflow will ... long-term samples, minimizing manual errors, improving the workflow ... errors such as mislabeling or inaccurate sample barcoding ... a vital role in blood fractionation, DNA extraction, ...
(Date:11/25/2015)... ANGELES and HOLLISTON, Mass. ... Technology, Inc. (Nasdaq: HART ), a biotechnology company ... that CEO Jim McGorry will present at ... December 1, 2015 at 2:30 p.m. PT. The presentation ... below) for 30 days. Management will also be available ...
(Date:11/25/2015)... 25, 2015 Orexigen® Therapeutics, Inc. (Nasdaq: ... a fireside chat discussion at the Piper Jaffray 27th ... . The discussion is scheduled for Wednesday, December 2, ... .  A replay will be available for 14 days ... , Julie NormartVP, Corporate Communications and Business Development , ...
(Date:11/24/2015)... ... November 24, 2015 , ... The United States Golf Association (USGA) today ... Green Section Award. Presented annually since 1961, the USGA Green Section Award recognizes an ... turfgrass. , Clarke, of Iselin, N.J., is an extension specialist of turfgrass ...
Breaking Biology Technology:
(Date:11/11/2015)... MINNETONKA, Minn. , Nov. 11, 2015   MedNet ... the entire spectrum of clinical research, is pleased to announce ... Partnerships in Clinical Trials (PCT) event, to be held ... will be able to view live demonstrations of ... platform, and learn how iMedNet has been able ...
(Date:11/4/2015)... November 4, 2015 --> ... report published by Transparency Market Research "Home Security Solutions Market ... Forecast 2015 - 2022", the global home security solutions market is ... by 2022. The market is estimated to expand at ... 2015 to 2022. Rising security needs among customers at ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, ... for U.S. distribution of its DNA library preparation ... and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq ... the preparation of NGS libraries for liquid biopsies--the ... diagnostic and prognostic applications in cancer and other ...
Breaking Biology News(10 mins):